

**Best of ASCO® India 2023 | Pune**  
**Program Director - Dr Tushar Patil**  
**23<sup>rd</sup> to 25<sup>th</sup> June, 2023**

**Day 1 | 23<sup>rd</sup> June, 2023 | Friday**

**Hall A**

**12:00 pm to  
1:00 pm**

**Lunch**

**1:00 pm to  
1:50 pm**

**Academic Session 1 - GU Cancer**

100-105

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

105-110

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

110-115

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

115-120

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

120-150

Panel Discussion

**1:50 pm to  
2:00 pm**

**Associated Meeting (Please refer to the Associated Meetings List)**

**2:00 pm to  
2:15 pm**

**Associated Meeting (Please refer to the Associated Meetings List)**

**2:15 pm to  
3:00 pm**

**Academic Session 2 - Gynaecological Cancer**

215-220

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

220-225

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).

225-230

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.

230-300

Panel Discussion

**3:00 pm to  
3:20 pm**

**Associated Meeting (Please refer to the Associated Meetings List)**

**3:20 pm to  
3:40 pm**

**Associated Meeting (Please refer to the Associated Meetings List)**

**3:40 pm to  
4:30 pm**

**Academic Session 3 - Breast Cancer 1**

340-345

Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

345-350

Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

350-355	Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).
355-400	Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.
400-430	Panel Discussion
<b>4:30 pm to 4:50 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>4:50 pm to 5:10 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>5:10 pm to 5:30 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>5:30 pm to 5:50 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>5:50 pm to 6:40 pm</b>	<b>Academic Session 4 - Breast Cancer (Metastatic)</b>
550-555	Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
555-600	Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
600-605	An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
605-635	Panel Discussion
<b>6:35 pm to 6:55 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>6:55 pm to 7:15 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>7:15 pm to 8:00 pm</b>	<b>Academic Session 5 - CNS</b>
715-720	INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
720-725	Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.
725-730	External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
730-735	Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
735-800	Panel Discussion
<b>8:00 pm onwards</b>	<b>Dinner</b>
<b>Day 2   24th June, 2023   Saturday</b>	
<b>Hall A</b>	
<b>9:00 am to 9:50 am</b>	<b>Academic Session 6 - GI Cancer 1 (Colorectal)</b>
900-905	PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX

	chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
905-910	Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
910-915	Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.
915-920	HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
920-950	Panel Discussion
<b>9:50 am to 10:10 am</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>10:10 am to 10:30 am</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>10:30 am to 11:15 am</b>	<b>Academic Session 7 - GI Cancer 2 (Non Colorectal)</b>
1030-1035	A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.
1035-1040	A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.
1040-1045	Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.
1045-1115	Panel Discussion
<b>11:15 am to 11:35 am</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>11:35 am to 12:10 pm</b>	<b>Academic Session 8 - Bone &amp; Sarcoma</b>
1135-1140	A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
1140-1145	Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
1145-1210	Panel Discussion
<b>12:10 pm to 12:30 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>12:30 pm to 1:00 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>1:00 pm to 1:20 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>1:20 pm to 1:50 pm</b>	<b>Lunch</b>
<b>1:50 pm to 2:40 pm</b>	<b>Academic Session 9 - Hemat (Lymphoma)</b>
150-155	SWOG S1826, a Randomized Study of Nivolumab (N) AVD versus Brentuximab Vedotin (BV) AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma
155-200	Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.

200-205	Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
205-210	Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
210-240	Panel Discussion
<b>2:40 pm to 3:00 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>3:00 pm to 3:50 pm</b>	<b>Academic Session 10 - Hemat (Myeloma)</b>
300-305	First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
305-310	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
310-315	Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
315-320	CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
320-350	Panel Discussion
<b>3:50 pm to 4:10 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>4:10 pm to 4:30 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>4:30 pm to 4:50 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>4:50 pm to 5:40 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>5:40 pm to 6:00 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>6:00 pm to 6:20 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>6:20 pm to 6:40 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>6:40 pm to 7:20 pm</b>	<b>Associated Meeting (Please refer to the Associated Meetings List)</b>
<b>7:20 pm to 8:10 pm</b>	<b>Academic Session 11 - Lung Cancer 1</b>
720-725	OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIa NSCLC
725-730	MSH3 and MSH6 gene polymorphisms: Association with lung cancer susceptibility and prognostic value in patients with NSCLC undergoing platinum-based chemotherapy.
730-735	IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
735-810	Panel Discussion
<b>8:10 pm onwards</b>	<b>Dinner</b>

**Day 3 | 25th June, 2023 | Sunday****Hall A****9:00 am to  
9:50 am****Academic Session 12 - Lung Cancer 2**

900-905

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

905-910

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

910-915

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).

915-950

Panel Discussion

**9:50 am to  
10:40 am****Associated Meeting (Please refer to the Associated Meetings List)****10:40 am to  
11:30 am****Academic Session 13 - Head & Neck Cancer**

1040-1045

PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)

1045-1050

Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.

1050-1055

10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.

1055-1100

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

1100-1130

Panel Discussion

**11:30 am to  
11:50 am****Associated Meeting (Please refer to the Associated Meetings List)****11:50 am to  
12:00 pm****Associated Meeting (Please refer to the Associated Meetings List)****12:00 pm to  
12:10 pm****Associated Meeting (Please refer to the Associated Meetings List)****12:10 pm to  
12:30 pm****Associated Meeting (Please refer to the Associated Meetings List)****12:30 pm to  
1:20 pm****Joint Session 3 with Asian Societies**

1230-1235

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types

1235-1240

First-line treatment of fecal microbiota transplantation for immune-mediated colitis

1240-1245

Assessment of YouTube as an information source for immune checkpoint inhibitors (ICIs).

1245-1250

Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621

1250-120

Panel Discussion

**1:20 pm to  
2:10 pm****Joint Session 4 with Medic LAWgic**

120-125

Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with

	early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
125-130	Reduced symptom burden after implementation of an electronic symptom management program.
130-135	Phase 3 RCT of dexamethasone versus placebo for chemotherapy induced fatigue in patients with advanced solid malignancies.
135-210	Panel Discussion on Medico Legal Aspects
<b>2:10 pm onwards</b>	<b>Lunch</b>